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Abstract
Background: Polycystic ovary syndrome (PCOS) is a multifactorial and heterogeneous
disease that has a potent inheritable component based on familial clustering. Despite
many studies in the genetic field of PCOS, the genes that are involved in the causes of
this syndrome have not been thoroughly investigated.
Objective: The purpose of this study was to establish the occurrence of the Trp64Arg
polymorphism of beta3 adrenergic receptor in non-obese women with PCOS.
Materials and Methods: This cross-sectional study was performed on 100 women
with PCOS and normal women as the control group in Imam Khomeini Hospital of
Tehran in 2016-2017. Peripheral blood sample (2 cc) was obtained from two groups for
genomic DNA based on the gene bank. Polymorphisms were genotyped by of using
ADRB3 Trp64Arg. Then the DNA was extracted by genomic kiagen kit. The primer was
analyzed for PCR based on gene bank by using Primer3 software and then confirmed
by primer Blast tool at NCBI site to conformity to the beta-3 adrenergic receptor gene.
The protein changes were assessment by the Clastal W software.
Results: The sequence analysis presented in NCBI, transcript variant 1, with the code
NM_000025.2, shows changes in the amino acid sequence of exon 1 in women
with PCOS. Polymorphism in the codon 64 encoding the amino acid tryptophan (W)
occurred in the nucleotide c.T190C, which changed the nucleotide T to C and then the
amino acid sequence of the tryptophan was altered to arginine pW64R.
Conclusion: T-C polymorphism is evident in the codon 64 of the adrenergic β3 receptor
in patients with PCOS. Therefore, Beta3 adrenergic receptor gene polymorphism
(Thr164Ile) associates with this syndrome in nonobese women.
Key words: Codon 64, Beta-3 adrenergic receptor, Polymorphism, Polycystic ovarian
syndrome.
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1. Introduction
Polycystic ovary syndrome (PCOS) has
heterogeneous clinical characteristics: polycystic
ovarian morphology (PCOM), hormone
imbalance, and metabolic disorders such as
insulin resistance (IR), diabetes, and obesity.
These conditions are the cause of infertility
through ovarian and follicular maturation
disorders (1, 2). Years of experimental and
human studies show that the overactivity
of the sympathetic nervous system (SNS)
can be the main cause for signs and
complications in PCOS. The adrenergic β3
receptor (ADR-B3) contains α1A, α1B, α1D,
α2A, α2B, α2C, β1, and β2 subgroups.
These adrenoceptors are located in the
adipose tissue, vascular endothelium, and
small intestine. The sympathetic activation of
B3 is involved in cardio-inhibition, glucose
uptake, lipolysis and relaxation of esophagus,
bladder, and colon. The human β3 receptor
gene has been localized to chromosome 8
(8p12-8p11.1). Β3ARs are also found in the
brain, in areas such as the hypothalamus
and the brain stem which can deliver multi-
synaptic innervation to white and brain
adipose depots (3). SNS-mediated brown
adipose tissue (BAT) thermogenesis activity
by diverse neurons found these areas
in brain structures. SNS afferent neurons
as thermoregulatory pathways control
thermogenesis in BAT by thermoregulatory
pathways with the interactions on the energy
balance systems. The selective agonists of
ADR-B3 can potently stimulate thermogenesis
and lipolysis (4). Hadri and coworkers in 1997
showed that the transition from a fasted
to a fed state in white and BAT in rats is
associated with a decrease in β3-adrenergic
receptor mRNA levels and β3-adrenergic
receptor responsiveness. They suggested
that there is a close relationship between
β3-adrenoceptor expression, plasma insulin,
and food intake (5). There are many reports
of the association of the ADR-B3 Trp64Arg
gene polymorphism with obesity and metabolic
syndrome (6-8). The gene encoding ADR-B2
polymorphism has been reported in hypertension
(9), asthma (10), and autoimmune disease
(11).
In this study, we investigated the
association of Trp64Arg (rs 4994) in the
first cytoplasmic region (Uniprot accession
p13945) as one variant in the ADRB3 gene in
PCOS.
2. Materials and Methods
2.1. Participants
This cross-sectional study was performed in
November 2015-2016 on women with PCOS.
In tota, 100 women with PCO participated from
the Reproductive Health Research Center of
Imam Hospital. All women were aged 20-40
years and the body mass index (BMI) <28 kg/m2.
They had no disease and no medication.PCOS
diagnosis was according to the joint criteria of
the European Society of Human Reproduction
and Embryology and the American Society
of Reproductive Medicine (ESHRE/ASRM)
(12).
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2.2. Sampling
In this study, 2cc of peripheral blood samples
from the study (women with PCO) and control
(normal) groups were collected in EDTA-treated
tubes and froze at -20°C.
2.3. DNA extraction
The extraction of genomic DNA from all samples
was done by using of the QIAamp DNA BIA Mini
Kit Qiamp (Cat ID // 51106). The genomic DNA
concentration and purity were assessed by using
of UNICO-spectrophotometer (S2100SUV). Purity
was determined using the standard A260/A280
and A260/A230 ratios.
2.4. Primer design
2.4.1. Primers used to amplify exon 1 from
the ADRB3 gene
Primer design was performed using Primer3
software for NG_011936.1 (Homo sapiens
adrenoceptor beta 3 (ADRB3), RefSeqGene on
chromosome 8) considering exon 1 and 2 regions
in CDS region and then by using primer blast tool
at NCBI site, it was approved in accordance with
the ADRB3 gene exon 1 and 2 in NM_000025.2
without any mismatch with another region of the
human genome. The fragment of interest was
amplified with the PCR primers listed in Table I.
2.4.2. Genotyping of adrenoceptor beta
3 gene: The amplification of sample for
preparation of PCR
25 μL PCR mixture was prepared including: 20
ng of DNA, 10 pmol of each primer, 0.2 mmol/L
of dNTPs, 2 mmol/L of MgCl2, and 1 U of Taq
DNA polymerase. The thermal cycling situation
for this study involved the original denaturation
stage at 95°C for 10 min followed by 35 series
of 95°C for 45 seconds, 59°C (exon 1) and 60°C
(exon 2) for 1 minutes, and 72°C for 45 sec,
and a final stage at 72°C for 10 minutes. All PCR
products were exposed to electrophoresis in buffer
of 1X TAE. The gel was marked with ethidium
bromide (10mg/ml) and visualized under UV. The
Gel documentation system was Transilluminator
and photographed (Bio-Rad Laboratories) (Figures
1, and 2) and analysis after stored at 4ºC (table
I). So, the fragments obtained were subjected to
electrophoresis in 1% agarose gel, and the size of
the fragments and quality of them were checked
(Figures 1, and 2). All samples were subjected to
sequencing for genotyping and patient sequence
analysis. The results were reproducible without any
discrepancies. The PCR results from four samples
were shown on 1% agarose gel for exon 1 and 2,
respectively, as shown below.
The sequence provided for ADRβ3 in NCBI,
transcript variant 1, with the code NM_000025.2
was used for investigation of changes in amino
acid.
Table I. Primer used in amplification of ADRB3 gene
Gene (NG_011936) Primer sequence (F, R, 5’ 3’) Product length (base pairs)
Exon 1 F:TAGAGAAGATGGCCCAGGCTR:CGAGCCGTTGGCAAAGC 1323
Exon 2 F:GCTGGGTTGGAGTAGGGATGT:AGAGGTTGTGGAAAGGCTGG 1340
https://doi.org/10.18502/ijrm.v18i3.6712 Page 167
International Journal of Reproductive BioMedicine Zafari Zangeneh et al.
Figure 1. Representative agarose gel image showing amplification of exon 1 of ADRB3 gene by using its specific primers: (1) 100
bp DNA ladder; (2) Negative control of PCR; (3) Control sample 1; (4) Control sample 2; (5) Patient sample 3; and (6) Patient sample
4.
Figure 2. Representative agarose gel image showing amplification of exon 2 of ADRB3 gene by using its specific primers: (1) 100
bp DNA ladder; (2) Negative control of PCR; (3) Control sample 1; (4) Control sample 2; (5) Patient sample 3; (6) Patient sample
4.
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2.5. Ethical consideration
This study was approved by the Ethical
Committee of Tehran University of Medical
Sciences (code: IR.TUMS.VCR.REC.2016.1329).
The study points were explained to these women
before they participated in the study, and informed
consent was obtained from all.
2.6. Statistical analysis
IBM SPSS statistics (Statistical Package for
the Social Sciences, version 24.0, SPSS Inc.,
and Chicago, IL) was used for analysis. To
check the correlation between natural and
mutated genotypes as well as homozygous
and heterozygote genotypes Chi-square test (chi2)




The quality and size of PCR products amplified
for ADRB3 exon 1 and 2 sequences were
analyzed using agarose gels. The comparison
of PCR products with DNA size markers
indicates that the PCR amplicons links to
the expected PCR products. According to
primer sequences (Table I), PCR product size
of 1323 and 1340 was confirmed (Figures
1, and 2) and their quality were good for
sequencing.
3.2. Sequencing results
Our results show that codon 64 is associated
with a polymorphism in women with PCOS. The
point of mutation in PCR sequencing has been
analyzed using Finch TV software in a woman with
PCOS (Figure 3).
Our results show that there is a significant
correlation between the presence of mutated
genotype and PCOS. This result confirms that the
mutagenic genotype can increases the chance of
developing polycystic ovaries in women. OR: 2.546
(95% CI: 1.02-5.367) P: 0.012. The power of the
study was also measured using the online GAS
software (0.718), which was a significant measure
that can indicate this study had high diagnostic
power.
In this study, no significant correlation was found
between homozygote and heterozygote genotype
(p = 0.301), which is due to the high power of
the study; it can be claimed that the sample size
did not have an effect on statistical results. For
complet, we used the Bootstrap test in which
samples in each group were tested 1,000 times.
Then, we used the Chi2 (it minimizes the sampling
error) where these results had no difference (Table
II).
Table II. Comparison of mutation and zygote in Beta3 adrenoceptor gene between women with PCOS and control group
Variables Control PCOS Odd ratio (OR) (95%CI) p-value Statistical power
68 (85%) 69 (69%)Wild mutant
12 (12%) 31 (31%)
2.546 (95%CI:1.02-5.367) 0.012
68 (85%) 79 (21%)Homozygote heterozygote
12 (15%) 21 (21%)
1.506 (95%CI: 0.691-3.286) 0.301
0.718
Data presented as n (%); Chi-square
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Figure 3. Sequencing of Codon64, c, mutant.
4. Discussion
In the present study, a significant association
of Trp64Arg beta 3-adrenoceptor gene
polymorphisms was observed in non-obese
women with PCOS (BMI < 28 kg/m2). Our result
suggests that women with this mutation genotype
have a significantly increased risk of PCOS (OR =
2.546, 95% CI: 1.02-5.367).
ADR-β agonists are potent activators of BAT
in mice and humans (13). All sub-groups of
Adrenoceptors β (β1−3) have an active role in the
metabolic processes like glycogenolysis, lipolysis,
and insulin secretion. These adrenoceptors can
cause metabolic syndrome (Mets) and PCOS.
Familial and twin studies show that there is
a genetic factor in women with PCOS with a
polygenic pattern of heredity (14, 15). The studies
on the PCOS exposure genes show that mostly
these genes are associated with insulin sensitivity
(16), sex hormone regulation (17), and metabolic
disorders (18).
Energy metabolism can be a reliable predictor
of weight gain. Overweight and obesity increase
the incidence of PCOS and so the increasing of
adiposity is considered a dominant characteristic
in 40 to 60% of women with PCOS (19).
There are at least four metabolic parameters
that can be predictive of weight gain: low
metabolic rate, low fat oxidation rates, low
spontaneous physical activity, and low activity
of SNS.
The BAT, as a specific kind of adipose tissue
with high activity, plays an important role in
the metabolism of the body due to its high
mitochondrial levels (20). Females with intact
ovaries who are more insulin sensitive are
protected from metabolic disorders because
their BAT ratio is higher than the total fat (21-
23). In an adult, Wang and coworkers showed
that BAT is strongly activated by an increase in
the circulating catecholamine concentration and
there is a significant amount of BAT expressing
β3-adrenergic receptor (23). Recent studies show
that there is an important role of the ADRβ3
axis in human energy metabolism. This finding
is confirmed by a common genetic codon of
Trp64 → Arg64 in ADRβ3, which can lead to
metabolic abnormalities such as low levels
of energy expenditure, high BMI (24), central
obesity (25), hyperinsulinemia/IR (26), high
blood pressure (BP) (27), type 2 diabetes (28),
and even with gestational diabetes mellitus
(29). These problems are also present in the
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symptoms and complications of women with
PCO.
Studies of the last decade show that β3-AR
controls BAT thermogenesis in humans (30, 31).
The SNS as the main regulator of BAT can be
firing the SAS sub serving BAT for releasing of
noradrenaline (NA) and activation of β3 subtype
(β3-AR). This trigger activates the lipolysis process
and mitochondrial uncoupling in BAT (31). A study
on the BAT as a thermogenic machine, as well as
the SNS-BAT axis, can help us to understand the
complex etiopathology of Mets and PCOS.
ADR-B3 (8p11.23) is essentially expressed in
white/brown adipose tissue and is involved in
thermogenesis thermogenesis and in the vascular
endothelium for glucose uptake, lipolysis and
cardio-inhibition/relaxation. The hypermethylation
of this gene in visceral tissue leads to metabolic
disorders (32).
In the present study, we investigated the
Trp64Arg polymorphism of the beta 3-adrenergic
receptor gene. For the selection of this codon,
we must consider two important principles in
women with PCOS as a dynamic study of two
interwoven aspects: (1) epigenetic mechanisms
and (2) neuroendocrine (autonomic/HPA/CRH
imbalance) disorder.
Novel aetiopathological and treatment concepts
can be raised from the fact that hypothalamic-
pituitary-adrenal (HPA) axis dysfunction in PCOS
like Mets could be initiated from sympathetic
hyper activity in two syndromes. The homeostatic
regulation of food intake is controlled by the
HPA axis through many cross-links in the neural
pathways of the neuroendocrine system (33).
Firstly, it is the neurons of corticotrophin-
releasing hormone (CRH) that contains the
initial component of the HPA axis and are
located in the paraventricular nucleus (PVN)
of the hypothalamus, which is a major center for
controlling the feeding behavior (34). One of the
other affective factors in BAT thermogenesis is
the CRH, which is another important regulator
of energy storage and adaptive thermogenesis.
CRH acts via specific G-protein-coupled receptors.
Real time RT-PCR and immunofluorescence
confirmed that CRH (CRH-R1/ R2) can target in
skeletal muscle and two types of adipose tissue:
white adipose tissue (WAT) and BAT (35). CRH-
R1/R2 receptors have been found in the stromal
cells, thecal and follicular fluid in human ovaries.
Ovarian CRH-like NA regulates steroidogenesis,
follicular maturation, ovulation, and luteolysis (the
so−called “aseptic” inflammatory) processes. In
human, peripheral infusion of CRH stimulates fat
oxidation and thermogenesis without changing
lipolysis in adipose tissue or sympatho-adrenal
activation. In normal female ovaries, there is no
CRH in the oocyte of primordial follicle (36). But
in the theca cells of womwn with PCO, CRH is
associated with the rich of sympathetic nerves
(37). In women with PCOS, the presence of CRH
with its inhibitory role in oocyte maturation might
be accompanied with the occurrence of follicle
atresia that is observed in this syndrome (38).
Zangeneh and coworkers in 2017 showed that
hyponeurotrophinemia and decreasing CRH level
in the serum of nonobese women with PCOS
could reflect a deficiency of neuronal stress
adaptation (39). This finding shows that central
CRH and ovary CRH in women with PCOS is
different from normal. Solinas and coworkers
in 2006 for the first time reported the skeletal
muscle’s thermogenesis directly stimulates by
CRH. They demonstrated that this thermogenic
effect requires both phosphatidylinositol 3-kinase
and AMP-activated protein kinase signaling, which
can control the thermogenesis in this tissue by its
protection against skeletal muscle lipotoxicity and
IR (40). IR in women with PCO is not generalized
in all tissues. In rat modeling of the knock-out
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of insulin receptors, hyperandrogenism and
anovulation enhanced (41). Defects in metabolic
function by insulin can occur in adipose and
muscle tissues, but in the ovaries, mitogen
and steroidogenic actions are maintained (42).
Most women with PCOS have metabolic IR,
partly due to obesity or due to the genetic
predisposition. Ovarian insulin receptor can
increases the response of theca cells to LH,
and by increasing the expression of P450c17
and 3β-HSD2 leads to elevate of androgen
production (43). In women with PCO, IR as a
metabolic abnormality has a significant link with
chronic inflammation, and polycystic ovarian
syndrome is a low-level chronic inflammation
disease. Many studies show that this inflammation
has an essential role in the IR and metabolic
consequences in women with PCOS (44, 45). The
set point of body weight is the balance between
energy intake and energy expenditure, and the
central role of insulin axis in energy imbalance
can contribute to the pathogenesis of obesity.
Insulin as the mediator of feeding-related can
increase thermogenesis. Metabolic activity of BAT
can be activated by agonists of β3-adrenoceptor,
and NA transporter (NAT) can block it which
is measurable using [18F] fluorodeoxyglucose
positron emission tomography/computed
tomography (PET/CT) in rat. By this method,
Baranwal and coworkers showed that the beta-
3-adrenergic agonist CL316, 243 has a potential
role on BAT for modulating blood glucose levels
(46).
Studies show that pharmacogenetics of β3AD
agonists and antagonists of NAT can help us to
treat obesity and diabetes (47, 48).
All of these bodies of evidences more confirm
that PCOS is a heterogeneous disease with
metabolic disorders and on the base of our
hypothesis; Trp64Arg polymorphism of beta3
adrenoceptor can increase the chance of PCOS.
5. Conclusion
The genomic studies help us for novel
aetiopathological and treatment concepts of
PCOS. T-C polymorphism is evident in the codon
64 of the ADR-B3 in patients with PCOS and
Beta3 gene polymorphism (Thr164Ile) associated
with this syndrome. We need to study the future
research that investigated the interactions of risk
genotypes, environmental factors, and epigenetic
encoding in the pathophysiology of PCOS.
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